AMAnatoliy I. Martynov

Anatoliy I. Martynov

*This is an algorithmically generated author record based on publicly available information.

Anatoliy I. Martynov has a total of 349 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Consensus Statement on the Management of Patients With Asymptomatic Hyperuricemia in General Medical Practice

    by Oksana M. Drapkina, Vadim I. Mazurov, Martynov I. Martynov, Evgeny L. Nasonov, Sergey A. Saiganov, Aleksander M. Lila, Roman A. Bashkinov, Irina N. Bobkova, Chokan T. Baimukhamedov, Inna Z. Gaydukova, et al.

    Hyperuricemia is a condition characterized by an increase of serum uric acid level above 360 µmol/L. It is known that high serum uric acid levels are not only the condition for the etiopathogenesis of gout but also an important risk factor for the development and progression of cardiovascular diseases, kidney and liver pathologies, type 2 diabetes, and others. This makes hyperuricemia a relevant issue in general therapeutic practice. Despite extensive evidence on the negative role of hyperuricemia in many internal organ diseases, the management strategy for patients with asymptomatic hyperuricemia in real clinical practice remains a subject of debate. This resolution represents an interdisciplinary consensus of experts from Commonwealth of Independent States, based on current evidence-based medicine data and proprietary registries. The proposed algorithm emphasizes the importance of a personalized approach to the treatment of hyperuricemia, taking into account the severity of comorbid conditions and the level of cardiovascular risk. Step-by-step recommendations are provided for general practitioners, family doctors, and a wide range of specialists in both non-pharmacological and pharmacological urate-lowering therapy. These guidelines aim to improve the quality of medical care for patients at high risk of socially significant diseases occurring together with asymptomatic hyperuricemia.


  • Open Access

    Diagnostics and Treatment of Esophageal Achalasia (Clinical Guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Society for the Prevention of Noncommunicable Diseases, REndO Endoscopic Society)

    by V. T. Ivashkin, A. S. Trukhmanov, I. V. Maev, O. M. Drapkina, A. I. Martynov, O. A. Storonova, E. A. Godgello, M. P. Korolev, T. L. Lapina, P. V. Pavlov, et al.

    Aim: to familiarize gastroenterologists, therapists, functional diagnostics and general practitioners (family doctors), radiologists, and endoscopists with modern methods of diagnosis and treatment of achalasia of the cardia.Key points. Achalasia is an idiopathic neuromuscular disease manifested by a functional disorder of the patency of the cardia due to a lack of coordination between swallowing, reflex opening of the lower esophageal sphincter, and the motor and tonic activity of the smooth muscles of the esophagus. The etiology of achalasia remains unclear. However, it is believed that the key role belongs to the changes in the myenteric (Auerbach’s) intermuscular plexus of the enteric nervous system of the esophagus, leading to loss of neuronal function. The following hypotheses have been proposed as the main mechanisms for the development of achalasia: genetic predisposition, exposure to viral infections, and idiopathic autoimmune triggers. Patients with suspected achalasia require a comprehensive instrumental examination, including esophagogastroduodenoscopy, timed barium esophagogram, and esophageal manometry. In recent years, high-resolution esophageal manometry has been recognized as the gold standard for achalasia diagnostics. To analyse the obtained data, the Chicago classification is recommended — it allows to ascertain the type of achalasia, which determines the choice of treatment method and the assessment of the prognosis of the therapy effectiveness. Treatment of achalasia can be pharmacological, endoscopic (pneumatic balloon dilation, peroral endoscopic myotomy, botulinum toxin injection), aimed at regulating the tone and motility of the esophagus and cardia while preserving all anatomical structures, and surgical (laparoscopic esophagocardiomyotomy, esophagectomy), in which the muscle fibers of the esophagus and esophagogastric junction are intersected or the altered esophagus is completely removed with simultaneous formation of an artificial esophagus from the stomach or colon (esophagoplasty).Conclusion. Implementation of the developed clinical guidelines can help to establish a diagnosis in a timely manner, which will lead to an improvement in the quality of medical care for patients with achalasia.

  • Open Access

    Diagnosis and Treatment of Gastroesophageal Reflux Disease (Clinical Guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Society for the Prevention of Noncommunicable Diseases, Scientific Community for Human Microbiome Research)

    by V. T. Ivashkin, A. S. Trukhmanov, I. V. Maev, O. M. Drapkina, M. A. Livzan, A. I. Martynov, T. L. Lapina, A. V. Paraskevova, D. N. Andreev, O. P. Alexeeva, et al.

    Aim. These recommendations are developed for practitioners in order to familiarize them with modern diagnostic methods, management features and pharmacotherapy of patients with gastroesophageal reflux disease (GERD).General provisions. GERD is the most common reason for patients to visit clinics. There are esophageal and extraesophageal manifestations of GERD. Patients' complaints of heartburn and regurgitation remain the most sensitive and specific clinical manifestations of GERD. The diagnosis of GERD is established on the basis of anamnestic data, instrumental examination (detection of reflux esophagitis during upper gastrointestinal endoscopy, detection of pathological gastroesophageal reflux with 24-hour pH-metry or/and 24-hour pH-impedance monitoring). Patients with suspected GERD and the absence of erosive and ulcerative changes in the mucous membrane of the esophagus or the presence of erosive esophagitis of Grade A according to Los Angeles Classification of Gastroesophageal Reflux Disease are recommended to conduct 24-hour pH-metry on PPI off to exclude or confirm the diagnosis of GERD. Patients with extraesophageal manifestations of GERD without classic symptoms (heartburn, regurgitation) are recommended to undergo 24-hour pH-impedance monitoring with discontinuation of proton pump inhibitor therapy. When deciding on surgical treatment, all patients need to perform high-resolution esophageal manometry and 24-hour pH-impedance monitoring. Complications of GERD include bleeding, strictures, Barrett’s esophagus and esophageal adenocarcinoma. The main groups of medications used in the treatment of GERD are proton pump inhibitors (PPIs), potassium-competitive acid blockers (P-CABs), alginates, antacids, and prokinetics. PPIs are the drugs of choice in the treatment of both symptoms of gastroesophageal reflux disease and existing erosive esophagitis. Combination therapy Rebamipide with PPIs increases the effectiveness of relief of GERD symptoms, as well as reduces the frequency of relapses.Conclusion. These clinical recommendations will improve the quality of medical care for patients with GERD.


  • Open Access

    Resolution of the Expert Forum "New therapeutic horizons of NAFLD"

    by Oksana Drapkina, Anatoly Martynov, Gregory Arutyunov, Igor Bakulin, Maria Livzan, Igor Maev, Ilia Egorov

    Aim. To present the materials of the Expert Forum "New therapeutic horizons of NAFLD," held on December 19, 2023, on the updated nomenclature of fatty liver disease (FLD), its main issues of diagnosis and treatment, the burden of cardiovascular risk in FLD patients. Executive Summary of the Resolution. It is recommended that the latest update of the FLD nomenclature be considered for adaptation to the clinical practice of doctors of all therapeutic specialties. Due to the high prevalence of a combination of non-alcoholic fatty liver disease (NAFLD) and an alcoholic component in the Russian Federation, it is essential to distinguish this subgroup of patients. Numerous clinical conditions associated with NAFLD include cardiovascular disease, pre-diabetes/type 2 diabetes mellitus, polycystic ovary syndrome, obstructive sleep apnea, sarcopenic obesity, cholelithiasis, and chronic kidney disease. Once a diagnosis of NAFLD has been made, further examination of patients should be aimed at detecting the presence of fibrosis using non-invasive methods such as transient liver elastography, FibroTest, and calculation of the FIB-4 fibrosis index. The original ademethionine can be considered a universal drug in treating NAFLD due to reducing oxidative stress and correcting concomitant fatigue and asthenia.


  • Open Access

    Consensus statement on the management of patients with asymptomatic hyperuricemia in general medical practice

    by O. M. Drapkina, V. I. Mazurov, A. I. Martynov, E. L. Nasonov, S. A. Saiganov, A. M. Lila, R. A. Bashkinov, I. N. Bobkova, Ch. T. Baimukhamedov, I. Z. Gaidukova, et al.

    Консенсус для врачей по ведению пациентов с бессимптомной гиперурикемией в общетерапевтической практике


  • Open Access

    Impact of urate-lowering therapy on the course of chronic kidney disease in patients with asymptomatic hyperuricemia: a meta-analysis of randomized controlled trials

    by Vadim I. Mazurov, Sergey A. Sayganov, Anatoly I. Martynov, Roman A. Bashkinov, Inna Z. Gaydukova, Kirill V. Sapozhnikov, Daria G. Tolkacheva, Natalia A. Sableva, Alexandra Yu. Tsinzerling, Сайганов Сергей Анатольевич, et al.

    The presented study has been carried out to identify the effect of urate-lowering therapy with xanthine oxidase inhibitors on glomerular filtration rate and serum uric acid in patients with asymptomatic hyperuricemia and chronic kidney disease. A systematic review of randomized controlled trials has been conducted; its results based on meta-analysis has been evaluated. A systematic search and selection of publications in Embase, PubMed, Cochrane Library, and eLibrary databases has been performed. The studied drugs were xanthine oxidase inhibitors: allopurinol and febuxostat. The study considered the following parameters such as efficacy endpoints, namely, glomerular filtration rate and serum uric acid after 3–15 months of follow-up. Clinical and methodological heterogeneity of the included randomized controlled trials has been assessed as well as publication bias and risk of systematic error. Synthesis has been performed using bivariate meta-analysis assessing residual statistical heterogeneity. 7 selected randomized controlled trials (1203 patients) have been included in the meta-analysis. This analysis revealed that medication urate-lowering therapy (allopurinol or febuxostat) was associated with higher glomerular filtration rate (+3.0 ml/min/1.73 m2; 95% confidence interval +0.4 to +5.6; p = 0.022) compared with the controls (placebo/no urate-lowering therapy) at 3–15 months of follow-up. Along with this, medication urate-lowering therapy (allopurinol or febuxostat) has been found to result in lower serum uric acid (−3.3 mg/dl; 95% confidence interval −3.8 to −2.8; р 0.001) compared to the controls (placebo / no urate-lowering therapy) at 3–15 months of follow-up. The results of the meta-analysis have demonstrated a positive role of allopurinol and febuxostat in increasing glomerular filtration rate and decreasing serum uric acid in patients with chronic kidney disease and asymptomatic hyperuricemia. The presented data suggest that therapeutic measures aimed at the elimination of asymptomatic hyperuricemia, including the use of xanthine oxidase inhibitors, may be important in slowing the progression of chronic kidney failure and may be additional factors of nephroprotection.


  • Modern view on treatment of iron and folic acid deficiency

    by A.I. Martynov, E.A. Lukina, A.G. Malyavin, O.D. Ostroumova, E.V. Shikh, M.V. Klepikova, S.S. Telkova, A.V. Dubinina

    Iron plays a key role in maintaining metabolic processes, energy exchange, respiration, immunobiological and oxidation-reduction reactions. Deficiency of this micronutrient is the most common nutrient deficiency worldwide and a cause of anemia in a large part of the population. The risk group includes women, especially during pregnancy, children and the elderly. Reduced intake of another significant micronutrient, folic acid, burdens the already existing iron-deficiency anemia (IDA) or acts as an independent disease. Due to the high prevalence of iron deficiency and IDA, the problem of development and optimization of the most effective and safe treatment remains relevant. As a result of this, on 22 of March, 2023 yr. a round table conference «Modern view on the treatment of iron and folic acid deficiency» was held under the moderation of A.G. Malyavin with the participation of speakers, who are key experts in this sphere. During the round table, the issue of balance between effective treatment of iron deficiency condition and high tolerability of iron supplements was discussed, and effective ways of treatment were proposed. In this connection, such aspects as iron metabolism in the different conditions, criteria for the iron deficiency, folates and IDA diagnosis, are examined in detail in the present review. Special attention is paid to the issues of low-dose oral forms of iron supplements application for the prevention and treatment of iron deficiency conditions, either with folate deficiency or without.


  • Open Access

    Outpatient Practice of Lipid-Lowering Therapy Prescription (According to the ARGO-3 Study)

    by M. V. Ezhov, N. M. Akhmedzhanov, T. E. Kolmakova, A. V. Tyurina, A. I. Martynov

    Aim. To study the frequency of prescriptions of various types of lipid-lowering therapy and their effectiveness in outpatient clinical practice based on the results of a questionnaire of primary care physicians.Material and methods. The study was performed in 2022 in 75 constituent entities of the Russian Federation with the participation of 1117 doctors working in outpatient clinics. Most of the doctors had work experience of 10-20 years or more. Doctors of polyclinics (therapists and cardiologists, etc.) before the start of the study received instructions, questionnaires for filling out, developed by the National Atherosclerosis Society. The frequency of prescriptions by primary care physicians of various types of lipid-lowering therapy and their effectiveness in terms of the frequency of achieving target levels of low-density lipoprotein cholesterol (LDL-C) was studied based on the results of a questionnaire.Results. Monotherapy with statins was prescribed in 55.2% of cases, free combination of rosuvastatin with ezetimibe – in 17.2%, single pill combination of rosuvastatin with ezetimibe – in 23.2%, combination therapy with PCSK9 inhibitors – in 4.1% of cases. Target levels of LDL-C ˂ 1.8 mmol/l and ˂ 1.4 mmol/l were achieved with statin monotherapy in 42.6% and 28.2% of cases, respectively, free combination of rosuvastatin with ezetimibe – in 61.7% and 39 .5%, a fixed combination of rosuvastatin with ezetimibe – in 67.8% and 48.5%, combination therapy with PCSK9 inhibitors – in 96.8% and 92.8% of cases.Conclusion. The single pill combination of rosuvastatin with ezetimibe is more effective in achieving target levels of LDL-C compared with statin monotherapy and therapy with free combination of statin with ezetimibe. Despite the fact that the target values of LDL-C when prescribing a combination with PCSK9 inhibitors were achieved in 96.8% and 92.8% of cases, they were used quite rarely at the outpatient stage of treatment in the Russian Federation.


  • Open Access

    "Focus on hyperuricemia". The resolution of the Expert Council

    by O. M. Drapkina, V. I. Mazurov, A. I. Martynov, I. Z. Gaidukova, D. V. Duplyakov, V. A. Nevzorova, O. D. Ostroumova, A. I. Chesnikova

    Мочевая кислота (МК) — это конечный продукт пуринового обмена, являющийся основной составляющей клеточных запасов энергии, таких как аденозинтрифосфат (АТФ), а также компонентом дезоксирибонуклеиновой (ДНК) и рибонуклеиновой (РНК) кислот. На сегодняшний день в Российской Федерации нормальным показателем МК в сыворотке крови считается 2 , по сравнению с пациентами с ИМТ 2[1].В крупных эпидемиологических исследованиях было показано, что ГУ представляет собой модифицируемый фактор риска развития и прогрессирования основных хронических неинфекционных заболеваний, таких как артериальная гипертензия (в том числе преэклампсия) [5,6], атеросклеротические сердечно-сосудистые заболевания (ССЗ) [7], хроническая сердечная недостаточность [8], сахарный диабет 2 типа (СД 2 типа), хроническая болезнь почек (ХБП), метаболический синдром [9], синдром обструктивного апноэ во сне [10]. Данные многочисленных эпидемиологических и проспективных исследований позволяют утверждать, что бессимптомная ГУ также выступает мощным, независимым и модифицируемым сердечно-сосудистым фактором риска. В связи с этим возникла необходимость разработать алгоритм инициации и интенсификации уратснижающей терапии у пациентов в зависимости от сердечно-сосудистого риска.С этой целью 02 декабря 2022 г. под председательством академика РАН О.М. Драпкиной под эгидой Российского общества профилактики неинфекционных заболеваний состоялся Совет экспертов «В фокусе гиперурикемия». Группа экспертов была представлена ведущими специалистами в области терапии, кардиологии, общей врачебной практики, ревматологии, клинической фармакологии. В результате объединения усилий была подготовлена резолюция, отражающая междисциплинарное мнение экспертов по различным аспектам проблемы гиперурикемии, и сформулированы предложения.


  • Open Access

    Features of prediction of fatal and non-fatal cases of ischemic stroke in patients with peripheral atherosclerosis in the long-term period

    by N. D. Kobzeva, A. I. Martynov

    Introduction. According to official statistics, stroke ranks second in the structure of mortality in Russia after coronary heart disease. Mortality and morbidity rates from this pathology among people of working age have recently increased by more than 30%. It should be clarified that the main cause influencing the development of acute cerebrovascular accident is hemodynamically significant atherosclerosis of the carotid vessels. Moreover, the pathological process itself can progress rapidly, or, on the contrary, remain stable for a long time.Aim. To assess the features of the development of fatal and non-fatal cases of ischemic stroke and develop an optimal approach to its assessment in patients with peripheral atherosclerosis in the long-term period.Materials and methods. The study included a group of 519 patients with atherosclerotic lesions of various vascular beds. The average age of the examined patients was 60.0 ± 8.7 years.All persons underwent standard biochemical studies, a set of instrumental studies, in the presence of clinical manifestations that arouse suspicion of atherosclerotic lesions of the vascular pools, coronary angiography, angiography of the renal vessels, brachiocephalic arteries and arteries of the lower extremities were performed. The second stage of the work included a prospective follow-up of patients for three years with an assessment of the endpoints.Results. In the course of the statistical analysis, it was revealed that factors such as a history of amputation of the lower limb (p = 0.048), chronic ischemia of the lower extremities (p = 0.016), atherosclerosis of the abdominal aorta (p = 0.024) influenced the risk of developing non-fatal ischemic stroke in examined patientsConclusions. The complex analysis carried out made it possible to develop an original nomogram for assessing the risk of developing fatal and non-fatal cases of ischemic stroke in the long-term period, which can be used in real clinical practice.